Skip to main content
CLDX
NASDAQ Life Sciences

赛尔迪克斯以每股29.00美元的价格定价3亿美元股票发行

feedReported by Reuters
Sentiment info
Neutral
Importance info
8
Price
$30.18
Mkt Cap
$2.081B
52W Low
$14.4
52W High
$34.52
Market data snapshot near publication time

summarizeSummary

赛尔迪克斯治疗公司已经定价其之前宣布的普通股公开发行，通过以每股29.00美元的价格出售10,345,000股股票，筹集了3亿美元。这是在公司早些时候宣布拟议发行之后，并在3月27日宣布其研究性药物barzolvolimab的二期试验数据非常积极之后。 这次发行提供了大量的资本注入，代表着公司当前市值的约14.4%，这对于资助正在进行的临床试验和管道开发至关重要。 虽然资本提高加强了资产负债表，但也对现有股东造成了重大稀释。 交易者将关注市场对稀释和战略资本注入用于管道推进的反应。

在该公告发布时，CLDX的交易价格为$30.18，交易所为NASDAQ，所属行业为Life Sciences，市值约为$20.8亿。 52周交易区间为$14.40至$34.52。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed CLDX - Latest Insights

CLDX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Celldex Seeks Shareholder Approval for 3.4M Share Increase in Equity Incentive Plan
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 06, 2026, 10:53 AM EDT
Source: GlobeNewswire
Importance Score:
7
Celldex Therapeutics Secures $345M from Public Offering, Underwriters Fully Exercise Option
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
Celldex Therapeutics Prices $300M Public Offering to Fund Barzolvolimab Commercialization and Pipeline
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Celldex Therapeutics Prices $300 Million Public Offering, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
CLDX
Apr 01, 2026, 9:48 PM EDT
Source: Reuters
Importance Score:
8
$300 Million Stock Offering Priced by Celldex at $29.00 Per Share
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 01, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex Proposes Public Stock Offering to Fund Barzolvolimab Commercialization
Sentiment: Negative
View Wiseek Article
CLDX
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex's Barzolvolimab Shows Profound, Durable Quality of Life Improvements in Phase 2 Urticaria Studies
Sentiment: Positive
View Wiseek Article
CLDX
Mar 01, 2026, 9:45 AM EST
Source: GlobeNewswire
Importance Score:
8
Barzolvolimab Retreatment Shows Profound Efficacy in Cold Urticaria and SD, Reinforcing Best-in-Class Profile
Sentiment: Positive
View Wiseek Article
CLDX
Feb 27, 2026, 2:45 PM EST
Source: GlobeNewswire
Importance Score:
9
Barzolvolimab Shows Sustained Efficacy, Disease Modification in Phase 2 Urticaria Data
Sentiment: Positive
View Wiseek Article
CLDX
Feb 25, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Celldex Therapeutics Advances Multiple Clinical Programs, Secures Liquidity Through 2027
Sentiment: Positive
View Wiseek Article